| Schedule of Basic and Diluted Earnings Per Share |
Shares used in the computation of the Company’s basic and diluted earnings per share are as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | (in thousands, except per share data) | | Three Months Ended September 30, | | Nine Months Ended September 30, | | | 2026 | | 2025 | | 2026 | | 2025 | | Numerator | | | | | | | | | | Net increase (decrease) in net assets resulting from operations | | $ | 93,568 | | | $ | 119,685 | | | $ | 266,251 | | | $ | 248,909 | | | Less: Total distributions declared | | (87,969) | | | (85,388) | | | (262,652) | | | (249,855) | | | Total Earnings (loss), net of total distributions | | 5,599 | | | 34,297 | | | 3,599 | | | (946) | | | | | | | | | | | | Earnings (loss), net of distributions attributable to common shares | | 5,555 | | | 34,042 | | | 3,568 | | | (947) | | | Add: Distributions declared attributable to common shares | | 87,267 | | | 84,752 | | | 260,320 | | | 247,749 | | | Numerator for basic change in net assets per common share | | 92,822 | | | 118,794 | | | 263,888 | | | 246,802 | | | Add: Income impact of assumed conversion of 2028 Convertible Notes | | 4,079 | | 4,116 | | 12,236 | | | 9,096 | | Numerator for diluted change in net assets per common share | | $ | 96,901 | | | $ | 122,910 | | | $ | 276,124 | | | $ | 255,898 | | | | | | | | | | | | Denominator | | | | | | | | | | Basic weighted average common shares outstanding | | 185,989 | | 180,360 | | 184,767 | | 175,633 | | Incremental shares from assumed conversion of 2028 Convertible Notes | | 13,387 | | 13,387 | | 13,387 | | 10,015 | | Common shares issuable | | 702 | | 611 | | 683 | | 603 | | Weighted average common shares outstanding assuming dilution | | 200,078 | | 194,358 | | 198,837 | | 186,251 | | | | | | | | | | | Change in net assets per common share: | | | | | | | | | | Basic | | $ | 0.50 | | | $ | 0.66 | | | $ | 1.43 | | | $ | 1.41 | | | Diluted | | $ | 0.48 | | | $ | 0.63 | | | $ | 1.39 | | | $ | 1.37 | |
|
| Schedule of Number of Anti-diluted Shares as Calculated Based on Weighted Average Closing Price of Common Stock |
The calculation of change in net assets resulting from operations per common share assuming dilution, excludes all anti-dilutive shares. For the three and nine months ended September 30, 2026 and 2025, the number of anti-dilutive shares, as calculated based on the weighted average closing price of the Company’s common stock for the periods, are as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended September 30, | | Nine Months Ended September 30, | | Anti-dilutive Securities | | 2026 | | 2025 | | 2026 | | 2025 | | Unvested common stock options | | 45 | | 1,527 | | 160 | | 1,217 | | | | | | | | | | | Unvested restricted stock awards | | 33,068 | | — | | 91,354 | | 1,094 | | | | | | | | | |
|